DGAP-Adhoc: HAEMATO AG successfully completes capital increase
|
DGAP-Ad-hoc: HAEMATO AG / Key word(s): Capital Increase/Corporate Action
HAEMATO AG successfully completes capital increase
29-March-2021 / 17:05 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad hoc of HAEMATO AG:
HAEMATO AG successfully completes capital increase
March 29, 2021
HAEMATO AG (ISIN: DE000A289VV1, WKN: A289VV) has successfully completed the capital increase which was announced on March 24, 2021. The capital increase was oversubscribed..
The Company increased its share capital by € 475,391.00 to € 5,229,307.00 by issuing a total of 475,391 no-par value bearer shares against cash contributions, excluding shareholders' statutory subscription rights, making partial use of the Authorized Capital 2018. The new shares carry dividend rights from January 1, 2020.
he capital increase was carried out in the maximum possible amount. The placement price set by the Executive Board of the Company with the approval of the Supervisory Board was € 31.00 per share. Due to the high demand, the new shares were sold to institutional investors in an accelerated private placement. Subject to the registration of the capital increase in the Commercial Register, HAEMATO AG will receive gross proceeds of approximately € 14.7 million from the capital increase.
The new shares are to be included in trading on the Open Market of the Frankfurt Stock Exchange (Basic Standard) without a prospectus.
The capital increase was accompanied by GBC Kapital GmbH.
HAEMATO AG intends to use the inflow of funds from the capital increase to finance its own brand business. The lay test for COVID19 ("Wondfo 2019-nCoV Antigen Test (Lateral-Flow Method) Self-Test") approved on March 23, 2021 is a first product in this strategic re-orientation of the company. Further own brands in the field of aesthetic medicine are planned due to the strongly growing demand for hyaluronic acid products as well as botulinuimtoxin.
HAEMATO AG
The Executive Board
About HAEMATO:
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of its business activities is on the growth markets of high-priced specialty pharmaceuticals. The main focus is on therapies for cancer, HIV and other chronic diseases.
HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures of the HAEMATO AG share:
Listed share class: Ordinary bearer shares
ISIN: DE000A289VV1
WKN: A289VV
Stock exchange symbol: HAEK
Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
[email protected]
29-March-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
| Language: |
English |
| Company: |
HAEMATO AG |
|
Lilienthalstraße 5c |
|
12529 Schönefeld |
|
Germany |
| Phone: |
+49 (0)30 897 30 86 70 |
| Fax: |
+49 (0)30 897 30 86 79 |
| E-mail: |
[email protected] |
| Internet: |
www.haemato.ag |
| ISIN: |
DE000A289VV1 |
| WKN: |
A289VV |
| Listed: |
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1179392 |
| |
| End of Announcement |
DGAP News Service |
1179392 29-March-2021 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
289,86 |
274,12 |
197,84 |
238,33 |
285,04 |
248,14 |
282,00 |
| EBITDA1,2 |
11,27 |
9,96 |
1,90 |
3,31 |
12,64 |
9,66 |
12,40 |
| EBITDA-Marge3 |
3,89 |
3,63 |
0,96 |
1,39 |
4,43 |
3,89 |
|
| EBIT1,4 |
9,42 |
8,50 |
-18,68 |
1,63 |
11,16 |
8,30 |
11,40 |
| EBIT-Marge5 |
3,25 |
3,10 |
-9,44 |
0,68 |
3,92 |
3,35 |
4,04 |
| Jahresüberschuss1 |
6,98 |
6,28 |
-1,17 |
-4,83 |
6,53 |
8,19 |
6,90 |
| Netto-Marge6 |
2,41 |
2,29 |
-0,59 |
-2,03 |
2,29 |
3,30 |
2,45 |
| Cashflow1,7 |
-8,35 |
0,56 |
-2,76 |
14,67 |
14,05 |
19,73 |
0,00 |
| Ergebnis je Aktie8 |
3,20 |
2,70 |
-0,50 |
-1,02 |
1,35 |
1,57 |
1,34 |
| Dividende8 |
3,00 |
1,00 |
0,00 |
0,00 |
1,10 |
1,20 |
3,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2022 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Harry Haseloff
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| Haemato |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| A289VV |
15,000 |
- |
78,44 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 9,38 |
15,39 |
0,61 |
7,55 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 0,55 |
3,98 |
0,32 |
5,93 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 1,20 |
0,70 |
4,67 |
18.07.2023 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 31.05.2023 |
31.08.2023 |
16.11.2023 |
17.05.2023 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -26,97% |
-31,73% |
-43,61% |
-15,25% |
|
|
HAEMATO AG DE000A289VV1